Evidence map›Paper›PMID 29276426›Full record

ArticleCurrent opinion in colloid & interface science2017

The Light at the End of the Tunnel-Second Generation HPMA Conjugates for Cancer Treatment.

Jiyuan Yang, Jindřich Kopeček

Abstract read
In one paragraph

Article in Current opinion in colloid & interface science, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. PD-L1 targeted antibody-polymer-Epirubicin conjugate prolongs survival in a preclinical murine model of advanced ovarian cancer.Journal of controlled release : official journal of the Controlled Release Society · 2025
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. HPMA copolymer-collagen hybridizing peptide conjugates targeted to breast tumor extracellular matrix.Journal of controlled release : official journal of the Controlled Release Society · 2023
    Article
  11. Chemical Approaches to Synthetic Drug Delivery Systems for Systemic Applications.Angewandte Chemie (International ed. in English) · 2022
    Review
  12. Review
  13. Review
  14. Thermoresponsive polymeric dexamethasone prodrug for arthritis pain.Journal of controlled release : official journal of the Controlled Release Society · 2021
    Article
  15. Review
  16. Review
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Jiyuan YangDepartment of Pharmaceutics and Pharmaceutical Chemistry/CCCD, University of Utah, Salt Lake City, UT 84112, USA.
Jindřich KopečekDepartment of Pharmaceutics and Pharmaceutical Chemistry/CCCD, University of Utah, Salt Lake City, UT 84112, USA.

Funding

Backbone Degradable Polymer-drug Conjugates for the Treatment of Ovarian CancerR42CA156933 · NCI · THERATARGET · PI KOPECEK, JINDRICH H. · 2014 to 2015
$995k
NCI NIH HHS R42 CA156933
6 · The paper itself

Abstract

It is almost four decades since

Indexed as

backbone degradable polymerscancercombination therapyHPMA (N-(2-hydroxypropyl)methacrylamide)polymer-drug conjugates

Identifiers

PMID29276426
PMCPMC5739067

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.